-
1.发明授权Methods for generating and screening fusion protein libraries and uses thereof 有权用于产生和筛选融合蛋白文库的方法及其用途公开(公告)号：US09109223B2
公开(公告)日：2015-08-18
申请号：US12097419
申请日：2006-12-22
申请人： Adrian Schwartz Mittelman , Jeannick Cizeau , Nicholas Ronald Glover , Glen Christopher MacDonald
发明人： Adrian Schwartz Mittelman , Jeannick Cizeau , Nicholas Ronald Glover , Glen Christopher MacDonald
CPC分类号： C12N15/1034 , C07K16/30 , C07K2317/21 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/92 , C07K2319/00 , C07K2319/55 , C12N15/1086 , C12P21/02 , C40B30/04 , G01N33/5014
摘要： The invention provides methods for generating fusion protein libraries, such as immunotoxin libraries. The invention also relates to libraries of recombinant cells encoding nucleic acid sequences comprising fusion proteins. In addition, the invention relates to the libraries themselves and the use of the libraries to screen for fusion proteins that are specific for target cells, such as cancer cells. Further, the invention relates to methods of improving fusion proteins and to the improved fusion proteins.
摘要翻译： 本发明提供了产生融合蛋白文库的方法，例如免疫毒素文库。 本发明还涉及编码包含融合蛋白的核酸序列的重组细胞的文库。 此外，本发明涉及文库本身以及文库用于筛选特异于靶细胞例如癌细胞的融合蛋白的用途。 此外，本发明涉及改善融合蛋白和改进的融合蛋白的方法。
-
公开(公告)号：US08697075B2
公开(公告)日：2014-04-15
申请号：US13297783
申请日：2011-11-16
申请人： Nicholas Ronald Glover , Glen Christopher MacDonald , Joycelyn Entwistle , Jeannick Cizeau , Francina C. Chahal
发明人： Nicholas Ronald Glover , Glen Christopher MacDonald , Joycelyn Entwistle , Jeannick Cizeau , Francina C. Chahal
IPC分类号： A61K39/00 , A61K39/395 , C07K16/30
CPC分类号： A61K39/0011 , C07K16/30 , C07K16/303 , C07K16/3046 , C07K16/3053 , C07K16/3069 , C07K2317/21 , C07K2317/41 , C07K2317/51 , C07K2317/55 , C07K2317/565 , C07K2317/92 , G01N33/57488 , G01N2500/10
摘要： The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the invention provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the cancer specific antibodies of the invention. Further, the invention provides a novel cancer-associated antigen and its uses thereof.
摘要翻译： 本发明提供癌特异性抗体的重链和轻链互补决定区的氨基酸和核酸序列。 此外，本发明提供癌症特异性抗体和包含附着于毒素或标记物的癌症特异性抗体的免疫缀合物及其方法和用途。 本发明还涉及使用本发明的癌症特异性抗体的诊断方法和试剂盒。 此外，本发明提供了一种新的癌症相关抗原及其用途。
-
公开(公告)号：US20100254982A1
公开(公告)日：2010-10-07
申请号：US11722420
申请日：2005-12-21
申请人： Nicholas Ronald Glover , Glen Christopher MacDonald , Joycelyn Entwistle , Jeannick Cizeau , Francina C. Chahal
发明人： Nicholas Ronald Glover , Glen Christopher MacDonald , Joycelyn Entwistle , Jeannick Cizeau , Francina C. Chahal
IPC分类号： A61K39/395 , C07K14/00 , C07H21/00 , C12N15/74 , C12N1/21 , C07K16/18 , C07K16/28 , G01N33/574 , A61K38/16 , A61K31/7088 , A61K39/00 , C12Q1/68 , A61P35/00
CPC分类号： A61K39/0011 , C07K16/30 , C07K16/303 , C07K16/3046 , C07K16/3053 , C07K16/3069 , C07K2317/21 , C07K2317/41 , C07K2317/51 , C07K2317/55 , C07K2317/565 , C07K2317/92 , G01N33/57488 , G01N2500/10
摘要： The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the invention provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the cancer specific antibodies of the invention. Further, the invention provides a novel cancer-associated antigen and its uses thereof.
摘要翻译： 本发明提供癌特异性抗体的重链和轻链互补决定区的氨基酸和核酸序列。 此外，本发明提供癌症特异性抗体和包含附着于毒素或标记物的癌症特异性抗体的免疫缀合物及其方法和用途。 本发明还涉及使用本发明的癌症特异性抗体的诊断方法和试剂盒。 此外，本发明提供了一种新的癌症相关抗原及其用途。
-
公开(公告)号：US20130217865A1
公开(公告)日：2013-08-22
申请号：US13743672
申请日：2013-01-17
申请人： Nicholas Ronald Glover , Glen Christopher MacDonald , Joycelyn Entwistle , Jeannick Cizeau , Denis Bosc , Francina C. Chahal
发明人： Nicholas Ronald Glover , Glen Christopher MacDonald , Joycelyn Entwistle , Jeannick Cizeau , Denis Bosc , Francina C. Chahal
IPC分类号： C07K16/30 , C07K14/415 , C12N9/10
CPC分类号： C07K16/2884 , A61K38/00 , A61K39/39558 , A61K45/06 , A61K47/6819 , A61K47/6829 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K2039/505 , C07K14/415 , C07K16/30 , C07K16/3015 , C07K2317/31 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/624 , C07K2317/626 , C07K2317/77 , C07K2319/55 , C12N9/1077 , G01N33/574 , G01N2333/471 , G01N2333/70585
摘要： The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a tumor specific antibody. In addition, the invention provides tumor-specific antibodies and immunoconjugates comprising the tumor-specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the tumor-specific antibodies of the invention.
摘要翻译： 本发明提供了肿瘤特异性抗体的重链和轻链互补决定区的氨基酸和核酸序列。 此外，本发明提供包含附着于毒素或标记物的肿瘤特异性抗体的肿瘤特异性抗体和免疫缀合物及其方法和用途。 本发明还涉及使用本发明的肿瘤特异性抗体的诊断方法和试剂盒。
-
5.发明授权公开(公告)号：US07750136B2
公开(公告)日：2010-07-06
申请号：US11971660
申请日：2008-01-09
申请人： Matthew Baker , Francis J. Carr , Koen Hellendoorn , Jeannick Cizeau , Glen Christopher MacDonald , Joycelyn Entwistle , Denis Georges Bosc , Nicholas Ronald Glover
发明人： Matthew Baker , Francis J. Carr , Koen Hellendoorn , Jeannick Cizeau , Glen Christopher MacDonald , Joycelyn Entwistle , Denis Georges Bosc , Nicholas Ronald Glover
IPC分类号： C07H21/04
CPC分类号： C07K16/30 , A61K38/00 , A61K47/6825 , A61K2039/505 , C07K14/415 , C07K2317/34 , C07K2317/55 , C07K2317/622 , C07K2319/00 , C07K2319/30 , C07K2319/33 , C07K2319/55
摘要： The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.
摘要翻译： 本发明提供具有生物活性的bouganin蛋白质的修饰形式，与非修饰的bouganin蛋白质相比，活化人类T细胞的倾向降低。 本发明还提供了与非修饰的T细胞表位肽相比，bouganin的T细胞表位肽和bouganin的修饰的T细胞表位肽，其具有降低的活化人T细胞的倾向。 本发明还提供了具有与附着于改良的bouganin蛋白的癌细胞结合的配体的细胞毒素。 还提供了使用本发明的细胞毒素和用于治疗人类癌症的药物组合物来抑制或破坏哺乳动物癌细胞的方法。
-
6.发明申请公开(公告)号：US20080219994A1
公开(公告)日：2008-09-11
申请号：US11971660
申请日：2008-01-09
申请人： Matthew Baker , Francis J. Carr , Koen Hellendoorn , Jeannick Cizeau , Glen Christopher MacDonald , Joycelyn Entwistle , Denis Georges Bosc , Nicholas Ronald Glover
发明人： Matthew Baker , Francis J. Carr , Koen Hellendoorn , Jeannick Cizeau , Glen Christopher MacDonald , Joycelyn Entwistle , Denis Georges Bosc , Nicholas Ronald Glover
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： C07K16/30 , A61K38/00 , A61K47/6825 , A61K2039/505 , C07K14/415 , C07K2317/34 , C07K2317/55 , C07K2317/622 , C07K2319/00 , C07K2319/30 , C07K2319/33 , C07K2319/55
摘要： The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.
摘要翻译： 本发明提供具有生物活性的bouganin蛋白质的修饰形式，与非修饰的bouganin蛋白质相比，活化人类T细胞的倾向降低。 本发明还提供了与非修饰的T细胞表位肽相比，bouganin的T细胞表位肽和bouganin的修饰的T细胞表位肽，其具有降低的活化人T细胞的倾向。 本发明还提供了具有与附着于改良的bouganin蛋白的癌细胞结合的配体的细胞毒素。 还提供了使用本发明的细胞毒素和用于治疗人类癌症的药物组合物来抑制或破坏哺乳动物癌细胞的方法。
-
7.发明授权Cytotoxins comprising modified bouganin toxin for the treatment of cancer 有权细胞毒素包含改良的bouganin毒素用于治疗癌症公开(公告)号：US08716234B2
公开(公告)日：2014-05-06
申请号：US12784820
申请日：2010-05-21
申请人： Matthew Baker , Francis J. Carr , Koen Hellendoorn , Jeannick Cizeau , Glen Christopher MacDonald , Joycelyn Entwistle , Denis Georges Bosc , Nicholas Ronald Glover
发明人： Matthew Baker , Francis J. Carr , Koen Hellendoorn , Jeannick Cizeau , Glen Christopher MacDonald , Joycelyn Entwistle , Denis Georges Bosc , Nicholas Ronald Glover
IPC分类号： A61P35/00
CPC分类号： C07K16/30 , A61K38/00 , A61K47/6825 , A61K2039/505 , C07K14/415 , C07K2317/34 , C07K2317/55 , C07K2317/622 , C07K2319/00 , C07K2319/30 , C07K2319/33 , C07K2319/55
摘要： The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.
摘要翻译： 本发明提供具有生物活性的bouganin蛋白质的修饰形式，与非修饰的bouganin蛋白质相比，活化人类T细胞的倾向降低。 本发明还提供了与非修饰的T细胞表位肽相比，bouganin的T细胞表位肽和bouganin的修饰的T细胞表位肽，其具有降低的活化人T细胞的倾向。 本发明还提供了具有与附着于改良的bouganin蛋白的癌细胞结合的配体的细胞毒素。 还提供了使用本发明的细胞毒素和用于治疗人类癌症的药物组合物来抑制或破坏哺乳动物癌细胞的方法。
-
公开(公告)号：US08383117B2
公开(公告)日：2013-02-26
申请号：US11570198
申请日：2005-06-10
申请人： Nicholas Ronald Glover , Glen Christopher MacDonald , Joycelyn Entwistle , Jeannick Cizeau , Denis Georges Bosc , Francina C. Chahal
发明人： Nicholas Ronald Glover , Glen Christopher MacDonald , Joycelyn Entwistle , Jeannick Cizeau , Denis Georges Bosc , Francina C. Chahal
IPC分类号： A61K39/395 , C07K16/00
CPC分类号： C07K16/2884 , A61K38/00 , A61K39/39558 , A61K45/06 , A61K47/6819 , A61K47/6829 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K2039/505 , C07K14/415 , C07K16/30 , C07K16/3015 , C07K2317/31 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/624 , C07K2317/626 , C07K2317/77 , C07K2319/55 , C12N9/1077 , G01N33/574 , G01N2333/471 , G01N2333/70585
摘要： The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a tumor specific antibody. In addition, the invention provides tumor-specific antibodies and immunoconjugates comprising the tumor-specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the tumor-specific antibodies of the invention.
摘要翻译： 本发明提供了肿瘤特异性抗体的重链和轻链互补决定区的氨基酸和核酸序列。 此外，本发明提供包含附着于毒素或标记物的肿瘤特异性抗体的肿瘤特异性抗体和免疫缀合物及其方法和用途。 本发明还涉及使用本发明的肿瘤特异性抗体的诊断方法和试剂盒。
-
9.发明申请Optimized Nucleotide Sequences of VB6-845 For Expression of Recombinant Proteins 有权优化VB6-845核苷酸序列用于表达重组蛋白公开(公告)号：US20100145023A1
公开(公告)日：2010-06-10
申请号：US12596188
申请日：2008-04-18
CPC分类号： C07K16/30 , A61K38/00 , A61K47/6817 , A61K47/6849 , C07K14/415 , C07K2317/52 , C07K2317/56
摘要： An optimized nucleic acid sequence encoding the immunoconjugate VB6-845 is described Modifications to the original VB6-845 include changes in the nucleic acid sequence encoding the VH region, CH region, CL region, VL region, the furm linker and the bouganm toxin. The optimized VB6-845 displays improved recombinant protein expression over the original in an E. coli expression system.
摘要翻译： 描述了编码免疫偶联物VB6-845的优化的核酸序列。对原始VB6-845的修饰包括编码VH区，CH区，CL区，VL区，furm连接体和bouganm毒素的核酸序列的变化。 优化的VB6-845在大肠杆菌表达系统中显示优于原始的重组蛋白表达。
-
公开(公告)号：US08263744B2
公开(公告)日：2012-09-11
申请号：US12596188
申请日：2008-04-18
CPC分类号： C07K16/30 , A61K38/00 , A61K47/6817 , A61K47/6849 , C07K14/415 , C07K2317/52 , C07K2317/56
摘要： An optimized nucleic acid sequence encoding the immunoconjugate VB6-845 is described Modifications to the original VB6-845 include changes in the nucleic acid sequence encoding the VH region, CH region, CL region, VL region, the furm linker and the bouganm toxin. The optimized VB6-845 displays improved recombinant protein expression over the original in an E. coli expression system.
摘要翻译： 描述了编码免疫偶联物VB6-845的优化的核酸序列。对原始VB6-845的修饰包括编码VH区，CH区，CL区，VL区，furm连接体和bouganm毒素的核酸序列的变化。 优化的VB6-845在大肠杆菌表达系统中显示优于原始的重组蛋白表达。
-
-
-
-
-
-
-
-
-
搜索结果
28 条记录 (耗时 0.023 秒)
